Milestone Pharmaceuticals’ novel, self-administered medication for paroxysmal supraventricular tachycardia has released alongside a patient support program.
David Bharucha, MD, PhD
Advertisement
David Bharucha, MD, PhD, is the chief medical officer of Milestone Pharmaceuticals.
Articles by David Bharucha, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
4
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
5